✦ LIBER ✦

135 A clinical phase I dose escalation, pharmacokinetic (PK) and pharmacodynamic (PD) study of BIBF 1120 in advanced cancer patients

✍ Scribed by K. Mross; F. Baas; M. Medinger; J. Drevs; R. Strecker; J. Hennig; M. Wolters; G. Stehle; M. Stefanic

Book ID: 118621320
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 148 KB
Volume: 2
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(04)80144-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

706 POSTER A phase I dose escalation pha

706 POSTER A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies

✍ S. Chia; K. Chi; C. Kollmannsberger; K. Paton; K. Bhagat; S. D'Aloisio; A. Das-G 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 66 KB

1243 Phase I dose-escalation study of co

1243 Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors

✍ H. Kaneda; I. Okamoto; T. Satoh; T. Arao; K. Nishio; A. Sarashina; K. Konishi; P 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Phase I Dose-Escalation and Pharmacokine

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

✍ Demetri, G. D.; Lo Russo, P.; MacPherson, I. R.J.; Wang, D.; Morgan, J. A.; Brun 📂 Article 📅 2009 🏛 American Association for Cancer Research 🌐 English ⚖ 238 KB

926 Pharmacokinetics (PK), clinical phar

926 Pharmacokinetics (PK), clinical pharmacodynamics (PD) and safety of chronic oral topotecan (T), in a phase I study

✍ J.H.M. Schellens; J.R. Eckardt; D.D. von Hoff; G.J. Creemers; C. Gerrits; W.J. L 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 146 KB

704 POSTER A phase I dose escalation and

704 POSTER A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients (HRPC)

✍ E. Raymond; F. Goldwasser; G. Bousquet; C. Le Tourneau; S. Faivre; H. de-Montser 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Phase I dose escalation and pharmacokine

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

✍ Danson, S; Ferry, D; Alakhov, V; Margison, J; Kerr, D; Jowle, D; Brampton, M; Ha 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB